Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing...
Hangzhou Polymed Biopharmaceuticals Raises Funds for Clinical Pipeline
China-based Hangzhou Polymed Biopharmaceuticals has reportedly completed a Pre-Series A+ financing round, raising an undisclosed...
Fosun Pharma Weighs Sale of India’s Gland Pharma Amid Market Interest
Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of...
Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...
Luye Pharma Initiates Phase II Study for LY 03014 in China
China-based Luye Pharma Group (HKG: 2186) has announced the first patient dosing in a Phase...
China’s Drug-Eluting Stent Procurement Results Announced
The national high-value medical consumables alliance procurement office has released the results of the successive...
Zhejiang Jiuzhou Pharma to Raise RMB 2.5 Billion via Private Placement
China-based Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456) has received approval from the China Securities...
Frontier Biotechnologies Partners with CASAPC for AIDS Prevention in China
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association...
Henlius Completes First Dosing in Head-to-Head Study of PD-1 Inhibitor HanSiZhuang
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
JancsiTech Raises Tens of Millions in Angel Round Led by Yuanbio Venture Capital
JancsiTech, a precision nuclear medicine specialist based in Shenzhen, has reportedly raised “tens of millions”...
FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment
US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...
Sino Biological to Invest RMB 1 Billion in Beijing Bio-Pharmaceutical Park
Sino Biological, Inc. (SHE: 301047) has announced plans to invest RMB 1 billion (USD 140...
Luye Pharma Launches Toludesvenlafaxine in China for Depression Treatment
China-based Luye Pharma Group (HKG: 2186) has officially launched its Category 1 chemical drug toludesvenlafaxine...
Hong Kong Researchers Identify New Target for Epilepsy Treatment
Researchers at the University of Hong Kong have published the results of a study that...
Hope Medicine Gains Global Approval for Phase II Trial of HMI-115
China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II...
Full-Life Technologies Acquires Focus-X Therapeutics to Expand Pipeline
Shanghai-headquartered Full-Life Technologies Ltd has announced the acquisition of New Jersey-based Focus-X Therapeutics. The move...
NMPA Launches Electronic Certificates for API and Pharmaceutical Product Exports
The National Medical Products Administration (NMPA) has released a notification regarding the initiation of two...
I-Mab Partners with Wuxi Diagnostics to Advance Biomarker-Driven Clinical Studies
China-based I-Mab (NASDAQ: IMAB) has announced a strategic partnership with compatriot firm Wuxi Diagnostics to...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...